Kolon’s TG-C Misses Phase 3 Endpoints

Company Kolon TissueGene Event Type Clinical Trial Results (Phase 3 — Negative) Modality Allogeneic Cell and Gene Therapy Asset TG-C Target TGF-β1 (Paracrine Modulation) Disease Area Knee Osteoarthritis Summary Kolon TissueGene’s allogeneic cell and gene therapy TG-C failed both co-primary endpoints in ACTiVION-II, a 531-patient…